TABLE 2.
Treatment group | Cytokine level (pg/ml) at the indicated time (days) of infectiona
|
|||||||
---|---|---|---|---|---|---|---|---|
IL-4
|
IL-10
|
IL-12
|
IFN-γ
|
|||||
60 | 120 | 60 | 120 | 60 | 120 | 60 | 120 | |
Sham | 752 ± 78 | 845 ± 85 | 4,680 ± 511 | 3,852 ± 665 | 13,211 ± 958 | 11,789 ± 1,214 | 712 ± 222 | 648 ± 65 |
Adjuvant | 988 ± 111 | 854 ± 70 | 4,997 ± 488 | 4,221 ± 326 | 15,021 ± 1,012 | 10,121 ± 1,014 | 911 ± 111 | 914 ± 102 |
Untreated | 2,654 ± 112 | 2,312 ± 522 | 16,021 ± 612 | 10,520 ± 1,584 | 38,021 ± 1,562 | 29,522 ± 2,011 | 2,615 ± 214 | 3,852 ± 545 |
P10 | 1,510 ± 88 | 1,121 ± 232 | 11,115 ± 522 | 6,250 ± 1,128 | 78,521 ± 2,123 | 63,160 ± 3,602 | 5,741 ± 612 | 6,412 ± 1,369 |
Fluconazole | 3,120 ± 166# | 3,321 ± 665# | 24,021 ± 1,021# | 27,321 ± 2,358# | 59,564 ± 1,855 | 63,555 ± 4,312 | 2,985 ± 251 | 3,621 ± 511 |
Fluconazole + P10 | 1,712 ± 98 | 2,011 ± 501 | 14,333 ± 633 | 22,619 ± 1,545 | 77,512 ± 2,213* | 88,888 ± 3,101* | 6,021 ± 452* | 9,021 ± 741* |
Ketoconazole | 5,312 ± 615# | 3,842 ± 852# | 26,313 ± 1,245# | 14,222 ± 2,354# | 45,326 ± 2,651 | 52,321 ± 2,988 | 3,011 ± 365 | 2,014 ± 636 |
Ketoconazole + P10 | 3,021 ± 188 | 2,011 ± 654 | 20,231 ± 999 | 11,050 ± 1,655 | 76,582 ± 2,365* | 56,500 ± 4,021* | 7,112 ± 522* | 8,844 ± 766* |
Itraconazole | 3,011 ± 318 | 3,015 ± 925# | 19,744 ± 823# | 17,455 ± 2,011# | 59,621 ± 1,025 | 54,114 ± 3,022 | 2,744 ± 329 | 2,113 ± 527 |
Itraconazole + P10 | 2,633 ± 215 | 1,855 ± 357 | 13,212 ± 655 | 11,456 ± 1,045 | 79,625 ± 1,653* | 44,112 ± 2,958 | 6,623 ± 444* | 9,571 ± 1,712* |
Amphotericin B | 1,546 ± 274 | 1,879 ± 603 | 17,100 ± 555# | 14,101 ± 1,789 | 33,265 ± 2,012 | 44,101 ± 3,012 | 3,111 ± 363 | 4,511 ± 951 |
Amphotericin B + P10 | 1,115 ± 63 | 2,011 ± 518 | 11,011 ± 456 | 13,011 ± 1,412 | 68,222 ± 2,322* | 64,111 ± 5,114* | 7,751 ± 454* | 6,255 ± 1,874* |
Trimethoprim-sulfamethoxazole | 5,311 ± 512# | 5,845 ± 1,232# | 23,121 ± 1,066# | 21,456 ± 1,654# | 33,665 ± 1,988 | 38,258 ± 2,145 | 2,655 ± 388 | 2,487 ± 358 |
Trimethoprim-sulfamethoxazole + P10 | 2,955 ± 311 | 3,695 ± 989 | 15,321 ± 633 | 14,258 ± 1,658 | 69,852 ± 2,011* | 60,115 ± 2,532* | 5,111 ± 522* | 10,421 ± 654* |
Boldface indicates a predominat Th-1 or Th-2-like response according to the cytokines produced (IL-12/IFN-γ or IL-4/IL-10, respectively). *, statistically significant difference (P < 0.05) relative to mice treated only with the drug; #, statistically significant difference (P < 0.05) relative to mice immunized with P10 and treated with the drug. Values are means ± standard deviations of measurements from 5 to 10 animals in each group. The whole experiment was repeated twice with reproducible results.